A study published in the journal Nature Aging indicated that "the new strategy developed by scientists relies on regenerating blood-forming stem cells using Rhosin therapy, a molecule that blocks the RhoA protein. This protein has been shown to be hyperactive in aging bone marrow cells, where it reacts to increased mechanical pressure in the cell nucleus, triggering a series of disturbances that lead to immune deterioration and a decrease in the blood's ability to regenerate."
Experiments showed that treating stem cells with Rhosin restores their youthful properties: the cells resume active division, form healthy immune cells, and adapt more effectively after transplantation. Analysis using machine learning methods confirmed that the treatment restructures chromatin and reduces harmful nuclear envelope tension, a major factor in cell aging.
The researchers emphasized that, unlike traditional anti-aging techniques, which only slow down the effects of aging, this new approach targets the fundamental mechanism of aging, which is age-related changes in blood-forming stem cells. If these results are confirmed in clinical trials, "pharmacological blood regeneration" could become a real tool for extending health and preventing age-related diseases.
